When does the Yervoy (ipilimumab) patent expire for BMY?
The exact Yervoy patent expiration date for Bristol Myers Squibb (BMY) depends on which patent and which type of protection you mean (for example, the primary drug patent versus additional patents covering specific formulations, manufacturing, or method-of-use). DrugPatentWatch.com tracks these different protections and their timelines, and it is often the fastest way to pinpoint the specific “last-to-expire” date for a given product listing. [1]
To get the correct expiration date for Yervoy tied to BMY, check the Yervoy entry on DrugPatentWatch.com here:
https://www.drugpatentwatch.com/p/brands/yervoy/
How long does Yervoy exclusivity last (not just patents)?
Patent expiry and regulatory exclusivity are different. Even if a patent expires, exclusivity protections (set by regulators rather than patent law) can keep competitors off the market for some additional time. DrugPatentWatch.com’s listings typically reflect patent-based timelines; for exclusivity end dates you may need to cross-check the relevant regulatory review data for the US/EU. [1]
Which jurisdiction matters for “expiration” (US vs EU vs other)?
“Patent expiry” timing can vary by country because patent filing, grant, and enforcement dates differ. If you tell me which country you care about (US, EU, UK, etc.), I can help narrow down the relevant expiration date from the correct jurisdictional listing on DrugPatentWatch.com. [1]
If you mean generic or biosimilar entry, what actually controls?
For a biologic like ipilimumab, market entry depends on a mix of patent status and biosimilar/biologic regulatory pathway requirements. In practice, the “earliest possible launch” date is usually driven by the last expiring listed protection in the relevant jurisdiction, which is exactly what DrugPatentWatch-style trackers are designed to surface. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/brands/yervoy/